Landmark Aspirin Study

An observational study by Cardiff University of over 520,000 cancer patients has shown:

- at any time following the diagnosis of some cancers the proportion of patients who were still alive was 20-30% greater in those taking aspirin, and

- the spread of cancer to other parts of the body was also substantially reduced in patients using aspirin.

While the study was not perfect, nor was it a clinical trial, it is hard to ignore. It provides some evidence to support consideration of our aspirin + fish oil/Omega 3 research we’ll call the AO3 Story. That is: when you take aspirin and fish oil/Omega 3, they have a chemical reaction which helps the body create Resolvins. These naturally occurring molecules mop up the treatment induced dead cancer cells that would otherwise fuel new tumours at a frightening rate of 100 times that of normal. Hopefully, Resolvins stop the all too common relapse.

The AO3 Story provides a plausible explanation of why aspirin helped cancer suffers in the Cardiff Study. See the full AO3 Story at: It suggests that you could have an even better result than the 20-30% benefit if you also took fish oil or regularly ate fish along with low dose aspirin, which some of the participants would have done.

To prove this, we would need a clinical trial costing millions and taking 5 to 10 years. In the meantime, we have to “make do” with the Cardiff Study, or the “unproven” AO3 Story lab studies. AO3 should give cancer patients at least the benefits of the Cardiff Study, plus the potential greater benefits of a higher production of Resolvins needed to deal with the surge in dead cancer cells following treatment. We see the Cardiff Study as encouraging evidence that we are on the right track. 

The recent ASPREE study found that Aspirin for healthy people aged 70+ is a bleed risk and provides little benefit. However, for cancer sufferers it seems a risk worth taking, according to the Cardiff Study as the benefits are undeniable. 

The bleed risk can be reduced by ensuring a low dose, coating the aspirin and dealing with gut bacteria that has recently been found to increase the risk of bleeding by 2.5 times.

Interestingly, this positive news raises the question of doctors drawing such information to the attention of their patients, as also noted in the Cardiff Study. This leads to some thorny legal, ethical and social issues we will explore in another blog post. That includes the pros and cons for patients supplementing their treatment with AO3, and more controversially, the risk for doctors of NOT drawing their patients attention to such information.

Another post will also consider whether current treatments of chemotherapy and radiotherapy which kill cancer cells that fuel new tumours need to be “softened” so the body’s immune system can better deal with the “cytokine storms”. This raises another risk by doctors of persisting with a blitzkrieg approach to treatments that overwhelm the body’s defences against dead cancer cells.

Improvements in our ability to measure Resolvins and dead cancer cells are needed to move on from the traditional “one-size-fits-all” shotgun approaches, towards more informed decisions. But they remain technical challenges. Regardless, a bigger challenge seems attitudinal in nature, and includes a reluctance to even investigate lab-based discoveries, let alone consider change without perfect proof.

The emerging age of more precise healthcare, along with patient collaboration and empowerment, demands full disclosure. Ironically, the legal bogeyman responsible for so much inertia in getting cures to patients, might be awakened to robustly lead the medical establishment to more innovative approaches, and faster cures, without the acceptance of relapses as the norm.

Good Enough Medicine

It’s big news for us to hear that experts are now recommending that exercise should be prescribed to cancer patients like any other medication. 

Though this is exciting in itself, the fact that this recent recommendation hasn’t been backed by the rigorous trials that has preceded other public announcements is very interesting. There is still plenty of research to be done here. For example, while we’re sure that exercise helps, we don’t know how. But that hasn’t stopped doctors and public health professionals from spreading the message: if it works, it works!

What we do know is:
• A recent study by Bath University has found that exercise increases the number of Natural Killer T-cells (a cell part of our immune system) by up to 10 times! It’s possible that exercise is beneficial to sickness (such as cancer) by boosting our immunity.
• Comprehensive research and perfect theories are no longer appropriate nor feasible in a fast-paced lifestyle. Patients don’t need - and often can’t afford – perfection. 

The delivery of timely therapies in the Western world (particularly in the cancer field) is hindered by academic bureaucracy, and walled empires, medical regulations and privacy laws. These are all valid concerns, but the medical field’s unwillingness to embrace more novel therapies without the backing of perfect trials is costing patients time and money. Loosening this, in combination with new technology, lower financial profit expectations and use of Big Data will assist in accelerating medical research. 

Clayten Christensen explores how the establishment will resist change in his classic business text “The Innovators Dilemma”, and its more recent off-shoot, "The Innovator's Prescription: A Disruptive Solution for Health Care". Intolerance of innovation persists despite it being far better that an organisation's own products or services disrupt them, rather than wait to be made irrelevant by upstart competitors.

The nature of medical research is changing. It might not happen overnight, but it is happening. The costs of researching, documenting and ‘proving’ the efficacy of medical therapies is too high and too slow. We always want “the best” but at what cost? Decades of time? Ten of millions of dollars? 

In some cases, we can’t afford to wait to know how or why things work. Sometimes, like exercise for cancer, they do. And that’s enough for doctors it seems. And it’s definitely enough for us.

With the rise of empowered patients like Intel's Bryce Olson, an evangelist of "Precision medicine", “Good enough medicine" is coming sooner than thought, despite the semantic conflict. 

Why? Why Not!

SinchHealth came about because of the 2017 publication of some very significant research for those of us with cancer. The issue is that too few in need, know about this research. We want your help to spread the word, improve things, and save lives. This blog will help keep you up to date.

Time is precious for cancer suffers so we will get straight to the point:

The Problem:
Chemotherapy and radiotherapy create cancer cell debris: dead and dying cancer cells. 
Cancer debris triggers an inflammatory response that may further stimulate aggressive tumour growth and metastasis that are difficult to resolve. 

The Solution:
This destructive consequence of gold-standard cancer therapies may be avoided/halted by Resolvins.[See]
Resolvins are molecules naturally produced by the body. They work to restore our cells to normal function during and after inflammation. We can help our body produce more Resolvins by taking Aspirin and Omega 3.[See]
The findings open the door to a new approach to reduce the risk of cancer recurrence.

The Bottom Lines:
Resolvins can prevent the double-edge to current cancer treatment: chemotherapy and radiotherapy increase the risk of cancer recurrence. [See]

Things have to change. That’s why we need your help to get the word out, and join us in igniting the call for better ways.

Meanwhile, we are working on a more detailed guide which includes suggestions re dosage and timing etc, so subscribe to our Facebook page and Twitter feed for updates. We would also love to hear your insights in this promising domain.